Earnings Feed
Start Free
Home/Filings/4/0001033408-10-000004
4//SEC Filing

MCNEILL JOHN A JR 4

Accession 0001033408-10-000004

CIK 0001003124other
View on SEC.govCompany Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 2:02 PM ET

Size

22.2 KB

Accession

0001033408-10-000004

Insider Transaction Report

Form 4
Period: 2010-07-30
PHARMACEUTICAL PRODUCT DEVELOPMENT INCPPDI
MCNEILL JOHN A JR
Director
Transactions
  • Award

    Stock Options (to buy)

    2010-07-30+9,090→ 9,090 total
    Exercise: $24.26From: 2011-07-30Exp: 2020-07-30→ Common Stock (9,090 underlying)
Holdings

  • Stock Options (to buy)

    Exercise: $13.12From: 2003-05-14Exp: 2013-05-13→ Common Stock (16,561 underlying)
    16,561

  • Common Stock

    (indirect: By Partnership)
    365,485

  • Stock Options (to buy)

    Exercise: $34.18From: 2006-05-17Exp: 2016-05-16→ Common Stock (4,113 underlying)
    4,113

  • Stock Options (to buy)

    Exercise: $19.19From: 2009-05-20Exp: 2019-05-20→ Common Stock (14,053 underlying)
    14,053

  • Stock Options (to buy)

    Exercise: $22.98From: 2005-05-18Exp: 2015-05-17→ Common Stock (5,650 underlying)
    5,650

  • Common Stock

    (indirect: By Trust)
    2,613,942

  • Stock Options (to buy)

    Exercise: $24.52From: 2010-05-20Exp: 2020-05-20→ Common Stock (10,496 underlying)
    10,496

  • Common Stock

    78,512

  • Stock Options (to buy)

    Exercise: $12.37From: 2002-05-15Exp: 2012-05-14→ Common Stock (12,421 underlying)
    12,421

  • Common Stock

    (indirect: By LLC)
    1,195

  • Stock Options (to buy)

    Exercise: $15.28From: 2001-05-15Exp: 2011-05-14→ Common Stock (8,281 underlying)
    8,281

  • Stock Options (to buy)

    Exercise: $32.67From: 2007-05-16Exp: 2017-05-15→ Common Stock (6,341 underlying)
    6,341

  • Stock Options (to buy)

    Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying)
    6,485
Footnotes (2)
  • [F1]The options vest in three equal increments on 7/30/2011, 7/30/2012 and 7/30/2013.
  • [F2]Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.

Documents

1 file

Issuer

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

CIK 0001003124

→
Entity typeother

Related Parties

1
  • filerCIK 0001033408

Filing Metadata

Form type
4
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 2:02 PM ET
Size
22.2 KB
View on SEC.gov